Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
GLP-1 (glucagon-like peptide-1) is a peptide hormone secreted from endocrine cells in the intestinal mucosa in response to meals. The major effects of GLP-1 are to increase glucose-induced insulin secretion and reduce glucagon release, but GLP-1 also inhibits gastric emptying rate and reduces appetite and bodyweight in obese subjects. In vivo studies using animal models of type 2 diabetes and in vitro studies using human islet cells have suggested that GLP-1 or GLP-1 analogues are also able to increase beta-cell mass, but in animal models of type 1 diabetes, there is much less evidence for a beta-cell preserving effect. This review summarizes the present knowledge of GLP-1 and its analogues regarding its role as a possible treatment in patients with type 1 diabetes. The studies that address the effect of GLP-1 and GLP-1 analogues on beta-cell mass in both type 2 and type 1 diabetes, as well as the potential of GLP-1 as an adjuvant therapy in islet cell transplantation, will be reviewed. Suggestions for future studies of GLP-1 treatment in type 1 diabetes may include early treatment in order to preserve beta-cell mass and prolong the remission period, but should also take a potential insulin sparing effect and changes in the risk of hypoglycemia into account.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“It is generally concluded that GLP-1-based treatments increase ß-cell mass in both type 2 diabetic and non-diabetic rodents through enhanced ß-cell proliferation, differentiation of new ß-cells from pancreatic duct progenitor cells and through inhibition of ß-cell apoptosis [1, 52, 64-68].”
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 has several actions in the body in relation to glucose regulation and weight control: It increases glucoseinduced insulin secretion, suppresses glucagon secretion (also glucose-dependently), inhibits gastric emptying, reduces appetite and promotes satiety [21].”
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 2×
“Several studies have indicated that the incretin effect in patients with type 2 diabetes is impaired or absent [23].”
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationTHE NOD MOUSE: A Model of Immune Dysregulation
Anderson, M. S., & Bluestone, J. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115643 · Cited by 1,113 · cited 1×
“The NOD (non obese diabetic) mouse is a widely used rodent model of type 1 diabetes since it develops spontaneous autoimmune diabetes with many similarities to autoimmune type 1 diabetes in humans [71].”
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“It acts through interaction with the GLP-1-receptor present in pancreatic islets, kidney, in certain areas of the brain [1] and in the heart [19, 20].”
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“Thus, GLP-1 treatment improves outcomes in models of cardiac injury such as experimental ischemia [38] and improves left ventricular function in patients following acute myocardial injury [39] as well as in patients with chronic heart failure [40] and treatment with GLP-1 has a favourable effect on endothelial functio…”
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“gon and increased glucose utilization [55].”
Self-citationSteffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695
Cited by
A Synthetic Optogenetic Transcription Device Enhances Blood-Glucose Homeostasis in Mice
Ye, H., Baba, M. D.-E., Peng, R.-W., & Fussenegger, M. (2011) · Science · doi:10.1126/science.1203535 · Cited by 467
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Self-citationKielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
Self-citationMinireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1
Brubaker, P. L. (2010) · Endocrinology · doi:10.1210/en.2010-0115 · Cited by 122
GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice
Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., & Calcutt, N. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01431.x · Cited by 87
“GLP-1 is also effective at regulating glycaemic control in newly diagnosed type 1 diabetic patients with residual β cells [4,5] and reducing blood glucose levels in type 1 diabetic”
Background
Metadata
- Authors
- Kielgast, U., Holst, J., & Madsbad, S.
- Venue
- Current Diabetes Reviews
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-11-01
- Volume
- 5
- Issue
- 4
- Pages
- 266-275
- ISSN
- 1573-3998 (ISSN-L)
- OpenAlex
- W2109810938
- Cited by
- 56
- References
- 31
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists. https://app.cochat.ai/papers/10.2174/157339909789804413
- The paper
- Kielgast, U., Holst, J., & Madsbad, S. (2009). Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists. Current Diabetes Reviews. https://doi.org/10.2174/157339909789804413
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.